products have been shown to modulate drug cytotoxicity characterized as the 'proximal', while overexpression of the through a 'distally' operative mechanism which regulates anti-apoptosis Bcl-2 or Bcl-x L relative to the pro-apoptosis Bax drug-induced apoptotic cell death. results also indicate that MRP overexpression does not confer resistance against paclitaxel. In addition, these findings suggest that, for Bcl-2 and Bcl-x L , enforced overexpression to high levels is necessary to induce paclitaxel resistance in HL-60
results also indicate that MRP overexpression does not confer resistance against paclitaxel. In addition, these findings suggest that, for Bcl-2 and Bcl-x L , enforced overexpression to high levels is necessary to induce paclitaxel resistance in HL-60
HL-60 cells were maintained in suspension culture in RPMI Introduction 1640 medium supplemented with 10% FCS. 18 HL-60/AR, HL-60/TAX1000 and HL-60/VCR cells were selected by culturing Multidrug resistance (MDR) in human AML remains a thera-HL-60 cells in the continuous presence of doxorubicin, paclitpeutic challenge. 1 Many reports in the past decade have demaxel and vincristine, respectively, and their biologic characteronstrated that overexpression of a variety of membrane or istics and MDR phenotype have been previously intracellular proteins confer an MDR phenotype in AML described. 17, 19, 20 These cells display a stable MDR phenotype cells. [2] [3] [4] The list of these gene products has been growing and despite their maintenance in drug-free media. To create HLnow includes the well-characterized membrane P-glyco-60/neo and HL-60/Bcl-2 cells, HL-60 cells were retrovirally protein (PGP), MRP and LRP. [1] [2] [3] [4] Their presence reduces intratransduced with the Bcl-2 and/or neomycin resistance cellular accumulation and/or drug-target interaction of antigenes. 8, 21 Recombinant expression plasmids pZip-Bcl-2 and leukemic drugs which are known to engage diverse pZip-neo were constructed and packaged as infectious intracellular targets, thereby preventing drug cytotoxicity and amphotropic retroviruses using PA317 cells, as previously mediating drug-resistance through 'proximal' mechanisms. 5 In reported. 8 21 Transduced cells were selected in RPMI 1640 by light microscopy. Five different fields were randomly selecmedium containing 10% FBS and 1 mg/ml G418 (Geneticin; ted for counting at least 500 cells. Percentage of apoptotic Gibco/BRL) for 2 weeks and then subcloned by limiting cells was calculated for each experiment. Cells designated as dilution. The selected populations were passaged twice per apoptotic were those which displayed the characteristic morweek.
phologic features of apoptosis including cell volume shrinkage, chromatin condensation and the presence of membrane bound apoptotic bodies. 24 The assessment of the percentage of apoptotic cells was confirmed by an additional indeWestern blot analysis of p26Bcl-2, Bax and Bcl-x L pendent observer who was blinded to the result of the first oncoprotein expressions observer.
The expression of PGP, MRP, Myc, Bcl-2, Bax, Bcl-x L , and p53 were determined by Western blot analyses according to Assessment of cytotoxicity of the MTT assay a previously described method.
17,22 A monoclonal anti-PGP C219 antibody was purchased from Centocor (Malvern, PA,
The MTT assay for cell cytotoxicity was used as previously USA). PGP expression encoded by the mdr-1 gene was further described. 25 The assay is based on the conversion of the confirmed by immunoblot analysis with the anti-PGP C494 yellow tetrazolium salt, 3-(3,5-dimethylthiazol-2-yl)-2,5-antibody (Signet Laboratories, Dedham, MA, USA). This antidiphenyltetrasolium bromide (MTT) to a colored formazan body only detects PGP encoded by the mdr-1 gene. A polyproduct by mitochondrial enzymes in the viable cells. Cells clonal anti-MRP was a gift from Dr SP Cole. 4 A mouse monowere incubated with the designated concentrations of paclitclonal antibody to human Bcl-2 (type 124, Dako, Carpinteria, axel for 24 h. Subsequently, drug-treated cells were washed CA, USA) or Myc (Santa Cruz Biotech, Santa Cruz, CA, USA) and resuspended in drug-free medium and 100 l aliquots or as well as rabbit anti-Bax or anti-Bcl-x antisera were also util-40 000 cells per condition were dispensed into 96-well flatized.
10,23 p53 expression was evaluated by utilizing the Ab6 bottomed microliter plates (Costar, Cambridge, MA, USA) and antibody (Oncogene Science, Cambridge, MA, USA), which incubated at 37°C for an additional 24 h. At the end of this detects both the mutant and p53 wt protein. Briefly, for immuincubation, 50 l of a 5 mg/ml solution of MTT (Sigma, St noblot analyses, protein was extracted from cells with a 100
Louis, MO, USA) was added to each well and the plates incumm Tris-HCl (pH 6.8) buffer, 150 mm NaCl, 10 mm Tris-HCl, bated for another 5 h at 37°C. Next, the plates were centripH 7.4, 5 mm EDTA, 1.0% Triton X-100. Appropriate protein fuged for 10 min at 500 g. After removing the supernatants, amounts (20 g) were subjected to sodium dodecyl sulfatethe formazan crystals were dissolved with 150 l of a 1:1 polyacrylamide gel electrophoresis (10% gel). After electro-DMSO/ethanol solution. The absorbance, A, of the wells was phoresis, proteins were transferred to nitrocellulose sheets (0. 5 measured with an Anthos plate reader (Anthos Labtec Instr., A at 100 V, at 4°C) for 1-3 h. The blots were blocked in 5% Salzberg, Austria) at 540 nm. The percentage of cell survival nonfat dry milk solution for 3 h at room temperature with was defined as: mean A of treated wells/A of untreated control gentle shaking (5% nonfat milk (wt/vol)/phosphate-buffered wells × 100%. saline (PBS)/0.02% sodium azide, pH 7.4). This was followed by incubation with the respective antibody (1:1000 dilution) at room temperature and then with anti-rabbit or mouse peroxidase-conjugated secondary IgG antibodies. Immune comRadioactively labeled drug accumulation studies plexes were detected with an enhanced chemiluminescence detection method by immersing the blot for 1 min in a 1: 6 cells were pelleted. The genconditions were determined by paired t test analyses. A oneway ANOVA was also applied to the results of the various omic DNA was extracted, purified and its purity was determined spectrophotometrically. 24 Agarose gel electrophoresis treatment groups, and post hoc analysis was performed using the Bonferroni correction method. of 1.0 g of DNA was performed as previously described.
24
Results and discussion gene products. Figure 1 that HL-60/AR cells accumulated reduced levels of doxorubicin which was partially reversed by co-treatment with verapaelevated Bcl-2 levels (1.8-fold) alone. Our studies have not addressed whether in these cells Bcl-2 or Bcl-x L overmil. 19 These findings indicate that overexpression of MRP reduces doxorubicin but not paclitaxel accumulation in HLexpression results form their transcriptional or post-transcriptional upregulation or due to the selection of those subpopula-60/AR cells. Figure 2 also demonstrates that co-treatment with verapamil (and cyclosporine, data not shown) completely nortions of cells that have higher endogenous expression of these malized paclitaxel accumulation in HL-60/TAX1000 and significantly increased it in HL-60/VCR cells. Not shown in Figure 2 , 3 H paclitaxel accumulation was not affected in HL-60/Bcl-2 or HL-60/Bcl-x L , and was similar to that of HL-60 and HL-60/AR cells. In previous studies we have demonstrated that the paclitaxel-uptake and paclitaxel-induced intracellular microtubular bundling and mitotic arrest are not affected; but paclitaxel-induced apoptosis is inhibited in those cells that overexpress Bcl-2 or Bcl-x L . 13, 30 Taken together, these It is important to note that, in HL-60/VCR and HL-60/TAX1000 cells, apoptosis is not triggered due to the reduced intracellular accumulation of paclitaxel, resulting in impaired, paclitaxel-induced microtubular bundling and mitotic arrest. This highlights a proximal mechanism of resistance. 17 In contrast, in HL-60/Bcl-2 or Bcl-x L cells paclitaxelinduced apoptosis is inhibited without impairment of paclitaxel-mediated proximal events, thus highlighting a distally compared to the high degree of protection by high Bcl-2 and Bcl-x L levels, relatively less protection was conferred against Exposure to higher concentrations of paclitaxel (5 m for 24 h) caused у90% loss of cell survival of HL-60/VCR cells, while high paclitaxel concentrations by PGP overexpression. This may be because, despite PGP overexpression following HL-60/TAX1000 cells were less susceptible to the cytotoxic exposure to 5 m paclitaxel, cytotoxic concentrations of the drug may accumulate over 24 h in HL-60/VCR and HL-60/TAX1000 cells. This is supported by our observation that the exposure of HL-60/VCR or HL-60/TAX1000 cells to concentrations of 3 H Taxol Ͼ1.0 m leads to greater intracellular accumulation of the drug (data not shown). Although not shown, for all of the experiments described above the findings in HL-60 cells were identical to those in HL-60/neo cells. The protective effect of high Bcl-x L or Bcl-2 levels (Bcl-x L : 10-fold, Bcl-2: five-fold) against paclitaxel in HL-60/Bcl-x L and HL-60/Bcl-2 cells, when contrasted with the absence of a similar effect of the coincidental but a lesser degree of overexpression of Bcl-x L and/or Bcl-2 in the other multidrug-resistant cells, suggests that there may be a threshold level of these antiapoptosis gene products above which significant protection is afforded against the cytotoxic effects of paclitaxel. This is also supported by the observations of Korsmeyer et al which indicate that significantly elevated levels of Bcl-2 and Bcl-x L , by forming heterodimers with Bax, reduce free Bax (to less than 50% of total Bax) and Bax homodimerization, and afford protection against apoptosis. 31, 32 In summary, data presented here highlight three important findings. First, they demonstrate that overexpression of Bcl-2 and/or Bcl-x L may develop coincidentally with PGP or MRP overexpression in multidrug-resistant human AML cells. Second, neither the low levels of the coincidental Bcl-x L (up cytotoxic effects of paclitaxel.
